Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
for Myelofibrosis
Drug: Ruxolitinib
Sites in Canton, Cincinnati +2 more locations
Sponsor: Telios Pharma, Inc.
Sex: All·Age: 18+
Code: NCT05280509·Phase 1, Phase 2·Recruiting·Listed Mar 2022